Thank you for joining us on World Dense Breast Day,  September 27th! Learn more HERE. 

 

DenseBreast-info, Inc.

Get Smart About Being Dense

EUROPE

Español

Blog

#WorldDenseBreastDay SUCCESS, FAQ Update

by

World Dense Breast Day
While final numbers are still being tallied, WDBD was a huge success. We saw posts in multiple languages and had participants from at least 64 countries. Increased awareness and desire for more education on the topic resulted in a 750% increase in DBI daily website traffic!

Many thanks to our supporters who participated in this education marathon! This year they were joined by private and hospital imaging centers, medical societies, medical journals, researchers/research supporters like the Breast Cancer Research Fund, local/national advocacy groups including Susan G. Komen, CME/CE developers, the media, celebrities, U.S. state and federal legislators, U.S. state/county health departments and even the National Cancer Institute!

Health Provider FAQ Update
An update to this Health Provider FAQ is now live: If a woman is a breast cancer survivor and has dense breasts, is mammography adequate screening?

#WorldDenseBreastDay, EUSOBI

by

Two events this week to be aware of:

#WorldDenseBreastDay, Sept 27
DBI social media posts will kick off on Sept 27 at midnight/US Eastern time and run for 24 hours. Over 100 posts in English and Spanish will highlight medically-sourced educational tools on the topic. For more info:https://densebreast-info.org/about-us/world-dense-breast-day/.

EUSOBI 2023, Sept 28
The European Society of Breast Imaging congress takes place 28-30 September in Valencia. The DenseBreast-info.org/Europe exhibition stand and promotional banner will be located at L13. Please Visit! Cheryl Cruwys, DBI’s European Education Coordinator, will be there.

Patient Brochures

by

DBI’s free downloadable patient brochure has just been updated! The single fold brochure (print/fold) is available in both English and Spanish. We extend thanks to our Patient Advisory Group and Medical Advisory Board for their input and perspectives!

DBI Spanish Language Materials & Support

by

News! The DBI Spanish language site SenosDensos.org is updated and more accessible. There has been a substantial increase in visits to DBI’s Spanish content and we are ready to address these educational needs!

In recognition of his long-term commitment to DBI Spanish language content development and expansion, we are delighted to announce that MAB member Dr. Daniel Lehrer, Breast Imaging Specialist and Medical Director at CERIM in Argentina, is now DBI Spanish Language Advisor. His tireless work assures that DBI content is, and will be, available to Spanish speaking women all over the world.

Research and MAB News

by

New Research
Finding it early saves lives and money. New research out in Current Oncology, Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing details that “…the cost of BC treatment is many orders of magnitude less when BC is diagnosed at an earlier stage, and that costs increase exponentially with stage. The magnitude of difference in cost for treatment of late-stage compared to early-stage BC has been previously noted to be 3–4 times; however, our study shows a cost differential of up to 36 times in magnitude when DCIS is compared with stage IV.”

Welcome!
DBI welcomes new Medical Advisory Board members Dr. Sheila Appavoo and Dr. Lars Grimm and welcomes back Dr. Jennifer Harvey! Our hardworking volunteer MAB members contribute to and review all website content.

DBI Study and Article, New Research

by

In Case You Missed it
Two DBI initiatives on risk assessment and supplemental screening published in the Journal of Breast Imaging continue to be popular:

Just Published
Out in Radiology, Comparative Performance of Contrast-enhanced Mammography, Abbreviated Breast MRI, and Standard Breast MRI for Breast Cancer Screening. Performance metrics were compared between pooled CEM and AbMRI evaluations from 246 participants (492 interpretations respectively) and 246 standard MRI evaluations from a single reader abstracted from the medical record. While the study found that the cancer detection rate and sensitivity of CEM was lower compared with standard MRI, importantly, readers were trained on CEM just prior to the study whereas MRI was used during the reader’s regular clinical practice. Differential experience interpreting CEM vs. MRI may have resulted in detection bias impacting the findings and pointing to the need for more radiologist training before widespread CEM use.

DENSE Trial 

by

A study of women with extremely dense breasts, the Dutch DENSE trial, has shown that adding MRI to mammography every two years improves cancer detection and reduces interval cancer rates. In a secondary analysis published in Radiology, women in the top third of enhancing volume of breast tissue on MRI were twice as likely to develop breast cancer as those in the lowest third. As incoming DBI MAB member Dr. Lars Grimm points out in an accompanying editorial, it is important to consider combinations of breast density and other risk factors that qualify women as “high risk” and therefore eligible for continued screening MRI under current guidelines.

#WorldDenseBreastDay 2023; Just Published

by

World Dense Breast Day, sponsored by DenseBreast-info.org, is now on the National Day Calendar. The one-day social media event will take place on Wednesday, September 27th. The purpose of the day is to use the power of social media to raise awareness about dense breasts and share medically sourced educational resources. Please mark your calendars! For more info and details about the worldwide success of last year’s inaugural event, click HERE.

Just Published
Important paper coauthored by DBI MAB member Dr. Jean Seely, Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years, showing reduced breast cancer deaths in Canadian provinces screening women 40-49 compared to those starting at age 50. “Decisions around BC screening in women in their 40s must weigh the potential harms and benefits of screening; however, this is not possible without accurate information concerning the impact of BC on mortality in women aged 40-49 years.”

NCCN Updates; South Australia News

by

South Australia
Breast Screen SA has announced that beginning August 8th 2023, South Australian women will be informed, in all screening clinics, of their individual breast density category.

 Screening flowchart
The Who Needs More Screening? flowchart has been updated to incorporate the recently released NCCN guidelines. The flowchart provides a roadmap for screening women with dense breasts or at higher risk and represents the consensus opinion of our Medical Advisory Board.

Density “Inform” in Canada

by

News Out of Canada
Ontario, Canada’s most populated province, has become the 7th province to require notification about breast density to women after screening mammography. Women will be informed of their specific density category (A, B, C or D) and the associated risks. Further, a draft recommendation to provide supplemental screening for women in category D (extremely dense breasts) is expected to be finalized in the Fall.

Two additional provinces, Saskatchewan and Newfoundland/Labrador have also committed to begin density notification in 2023. That will bring the total number of provinces with some level of density “inform” requirement to 9 (out of 10).  Please visit DenseBreastsCanada.ca for more info.

Find It Early Act (HR 3086)

by

A reminder that The Find It Early Act needs your support. This bill would ensure that all U.S. health insurance plans cover screening and diagnostic breast imaging with no out-of-pocket costs for women with dense breasts or at higher breast cancer risk. Your congressperson would benefit from hearing your perspective about the legislation. In-person visits or phone calls from constituents are motivating to elected officials. And, representatives that sign on as bill co-sponsors help the bill’s momentum.

Please take action: See DBI’s Find It Early Act webpage for “Lobbying 101” info on how to contact a congressperson, how to schedule a meeting, what to bring, what to ask, and follow up suggestions.

NCCN Guidelines; Missouri insurance law

by

Updated National Comprehensive Cancer Network (NCCN) Breast Cancer Screening and Diagnosis guidelines just out (accessible with free registration). For average risk women, the screening guideline includes:  “Consider supplemental screening for those with heterogeneously or extremely dense breasts.” And for women at increased risk, “Consider contrast-enhanced mammography (CEM) or molecular breast imaging (MBI) for those who qualify for but cannot undergo MRI. Whole breast ultrasound may be done if contrast-enhanced imaging or functional imaging is not available/accessible.”

U.S. State Insurance Law
A new insurance law for no-cost breast imaging has been signed into law in Missouri. While Missouri has an existing law for expanded breast imaging, this act “prohibits cost-sharing requirements under coverage provided for diagnostic breast examinations, supplemental breast examinations, or low-dose mammography screenings.” Exceptions apply. Please see DBI’s Legislative Info tab for updated details.

New RI Insurance Law & More

by

U.S. State Insurance Law
A new insurance law for expanded breast imaging has been signed into law in Rhode Island (copays/deductibles apply). Please see DBI’s Legislative Info tab for updated details.

Just Published
New in JACR, authored by DBI’s Chief Scientific Advisor Dr Wendie Berg, Analytic Hierarchy Process Analysis of Patient Preferences for Contrast-Enhanced Mammography (CEM) versus MRI as Supplemental Screening Options for Breast Cancer. The study showed that 70% of women who had both CEM screening and MRI preferred CEM. 97% of women with claustrophobia favored CEM. For women for whom positioning was most important, only 54% favored CEM. Healthcare providers should include discussion of these factors as part of shared decision making with patients desiring supplemental screening.

Educational Opportunities

  • The Association for Medical Imaging Management (AHRA) 50th anniversary annual meeting –  Executive Director JoAnn Pushkin’s presentation, Dense Breasts: New FDA Reporting Standard, Insurance Laws, Educational Tools, will be on Sunday July 9th.
  • In collaboration with the National Women’s Health Network (NWHN), DBI will participate in webinar Find It Early, on Friday July 14th from 12:00-1:00pm/EST. Keynote Speaker Rep. Rosa DeLauro, sponsor of the Find it Early Act, will be joined by DBI’s JoAnn Pushkin and NWHN’s Denise Hyater-Lindenmuth.

Updated Screening Flowchart & Recently Published

by

Who Needs More Screening? 
Just updated! One of the most popular DBI website tools is the screening decision support flowchart Who Needs More Screening?. The flowchart has just been updated and can be found in the For Providers tab. In the absence of national screening guidelines for women with dense breasts or at higher risk, the flowchart provides a roadmap and represents the consensus opinion of our Medical Advisory Board.
 
Recently Published 
Analysis of over 2.6 million mammogram results from the Breast Cancer Surveillance Consortium confirms greater prevalence of dense breasts in Asian women (66%) than non-Hispanic (NH) White women (45%), Hispanic women (45%), or Black women (37%). Breast density is inversely related to body mass index (BMI) and decreases with age and menopause. After correcting for BMI, age, and menopausal status, Black women were more likely to have dense breasts than NH White or Hispanic women. https://www.ncbi.nlm.nih.gov/pubmed/37284771

Nebraska insurance law, Just published

by

State Insurance Law
Legislation for expanded breast imaging insurance coverage has been signed into law in Nebraska. Please see DBI’s Legislative Info for updated map and table details.

Just Published
In Cancer, coauthored by DBI MAB member Dr Sally Herschorn, Breast cancer risk characteristics of women undergoing whole-breast ultrasound screening versus mammography alone.  Many women at high risk of screening mammography failure do not currently undergo supplemental screening beyond mammography.  Health care provider and patient awareness of other breast cancer risk factors beyond breast density, including family history and prior benign biopsies, is important in identification of women at high risk of mammography screening failure (interval cancer or advanced breast cancer) who should be recommended for supplemental screening with ultrasound or especially MRI. It is important to recognize that limiting supplemental screening to women at intermediate- to high-risk by the BCSC model would fail to identify 30-40% of women with dense breasts who will experience interval cancer and about 60% of all women who will develop advanced breast cancer.

Canadian Task Force Guidelines, Of Interest

by

Canada
The Canadian Task Force, Canada’s source of evidence-based clinical prevention guidelines for primary care providers, just announced it is “fast tracking” updates to their 2018 breast cancer screening guideline. Draft recommendations are due in late fall 2023.

Of Interest

Sign Up for Our Newsletter

Get news updates from DenseBreast-info.org in your inbox

Sign Up Today!